AbbVie Win on Humira Patent Portfolio Thwarts Antitrust Attacks – Bloomberg Law

  1. AbbVie Win on Humira Patent Portfolio Thwarts Antitrust Attacks  Bloomberg Law
  2. Analysis | This Arthritis Drug Deserves Its Aggressive Patent Protection  The Washington Post
  3. AbbVie wins appeal in antitrust case over Humira ‘patent thicket’  Reuters
  4. AbbVie’s Humira Patent Settlement Not A Violation Of Sherman Antitrust Act, Seventh Circuit Affirms – Patent – United States  Mondaq
  5. U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition  STAT
  6. View Full Coverage on Google News